

## Closing the precision oncology gap

We create clarity for patients and their clinicians by removing barriers to precision oncology testing in order to make timely, personalized cancer treatments a reality for all.

## Distributed comprehensive genomic profiling (CGP)

All patients deserve to have access to best-in-class genomic testing. PGDx is dedicated to empowering personalized care for all patients by bringing precision oncology testing to where they are.



Democratizing access to CGP with distributed kits



Delivering rapid insights to guide personalized treatment decisions



Elevating the standard of cancer care for all

## Actionable insights | Personalized care

The PGDx elio™ tissue complete test enables rapid and actionable genomic insights for all patients with advanced cancer. Our FDA-cleared and CE-IVD-marked comprehensive tumor profiling kit is available for pathology labs to help every patient receive the personalized treatment options they deserve.



### PGDx elio tissue complete:


A tumor tissue CGP IVD test

- ✓ FDA cleared, CE-IVD marked
- ▼ 505 solid tumor-related genes
- ✓ Highly accurate somatic mutation identification including SNVs, indels, TMB, MSI, and select amplifications (1) and translocations (4)

For in vitro diagnostic use.

# Streamline your NGS workflow

From extracted DNA to automatically generated clinical reports, PGDx has developed methods to optimize your NGS workflow and results. Streamline your lab with our proven technology that delivers high-quality CGP insights.





# Comprehensive biomarker analysis and discovery for cancer research

Accelerate novel discoveries in your precision oncology research programs with our highly sensitive and accurate assays that are backed by advanced proprietary bioinformatics.



#### PGDx elio tissue complete:

A tumor tissue CGP assay

- ✓ Customizable reporting
- **▼** 505 solid tumor-related genes
- ✓ Somatic mutation identification: SNVs, indels, TMB, MSI, select amplifications (28) and translocations (23)

### PGDx elio plasma complete:

A liquid biopsy CGP assay

- >95% concordance with comparator methods
- ✓ Somatic mutation identification: SNVs, indels, bTMB, MSI, LOH, select amplifications and translocations

### PGDx elio plasma resolve:

A focused liquid biopsy assay

- FDA breakthrough device designation on MSI
- 33 full coding genes for clinically relevant genes based on professional guidelines
- Somatic mutation identification: SNVs, indels, MSI, select amplifications and translocations

For Research Use Only. Not for use in diagnostic procedures.



**In-House:** Our distributed kit model facilitates in-house precision oncology



**Full Control:** Maintain control of samples and a rich feed of molecular data



**Robust:** >90% sample success rate with >99% repeatability for actionable variants

# Unlock a deeper understanding of tumor biology

PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab with timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.

- Automated: Turn-key workflow simplifies adoption and scaling
- Accurate: 100x more high-quality training data than other pipelines
- Unparalleled: Proven artificial intelligence-based approach